Parkinson's Disease

Michigan

59 Parkinson's Disease Trials near Michigan

Power is an online platform that helps thousands of Parkinson's Disease patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Bemdaneprocel for Parkinson's Disease

Farmington Hills, Michigan
Study BRT-DA01-301 is a Phase 3 multicenter, randomized, sham surgery-controlled, double-blind study to assess efficacy and safety of bemdaneprocel in approximately 102 adults with Parkinson's Disease (PD).
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:45 - 75

102 Participants Needed

Tavapadon for Parkinson's Disease

West Bloomfield, Michigan
This trial is testing a medication called tavapadon to see if it is safe and effective for people with Parkinson's Disease. The medication aims to help manage symptoms like tremors and stiffness by targeting specific parts of the brain.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:40 - 80

992 Participants Needed

ND0612 for Parkinson's Disease

Madison, Wisconsin
This is a multi-center, randomized, double-blind, double-dummy, active controlled clinical Study. Following a screening period, eligible subjects will be enrolled to an open-label oral IR-LD/CD adjustment period; then an open-label ND0612 conversion period; then after optimization periods subjects will be randomized to receive either ND0612 or its matching Placebo with IR-LD/CD. Subjects can continue to an optional open-label extension period.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:30 - 80

381 Participants Needed

BHV-8000 for Parkinson's Disease

Farmington Hills, Michigan
A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2, 3
Age:40 - 85

550 Participants Needed

CVN424 for Parkinson's Disease

Milwaukee, Wisconsin
This is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations. Participants will be randomized to receive once-daily oral doses of either 75 milligrams (mg) CVN424 or 150 mg CVN424, or a matching placebo for 12 weeks. Participants who successfully complete this study and retain eligibility/suitability will be invited to participate in a future open-label extension (OLE) study.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:30+

330 Participants Needed

ABBV-951 Infusion for Parkinson's Disease

Milwaukee, Wisconsin
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how safe and effective ABBV-951 is in adult participants with PD. Adverse events and change in disease activity is evaluated. ABBV-951 is an investigational (unapproved) drug containing Levodopa Phosphate/Carbidopa Phosphate (LDP/CDP) given as an infusion under the skin for the treatment of Parkinson's Disease. Adult participants with advanced PD and who have completed M15-736 or M20-339 study will be enrolled. Approximately 130 participants will be enrolled in the study in approximately 60 sites in the United States and Australia. Participants will receive continuous subcutaneous infusion (CSCI) (under the skin) of ABBV-951 for 96 weeks during the Primary Treatment Period and during the optional Extended Treatment Period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical and remote telephone assessments, blood tests, checking for side effects, and completing questionnaires.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:30+

118 Participants Needed

Apomorphine Infusion for Parkinson's Disease

West Bloomfield, Michigan
This is a Phase 3, multicenter, open-label, safety and tolerability study of continuous apomorphine infusion in subjects with advanced Parkinson's Disease (PD) whose motor fluctuations remain unsatisfactory with levodopa (or levodopa/carbidopa) and at least one other class of drugs or mode of therapy for PD.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:30+

99 Participants Needed

CREXONT ER for Parkinson's Disease

Farmington Hills, Michigan
The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4

220 Participants Needed

Pimavanserin vs. Quetiapine for Psychosis in Parkinson's Disease

Ann Arbor, Michigan
Patients with Parkinson's disease (PD) sometimes experience symptoms affecting their movement, such as slowness, tremor, stiffness, and balance or walking problems. Many patients also have other symptoms not related to movement, called non-motor symptoms, which may affect one's mood or emotions, memory or thinking, or cause one to see or hear things that aren't real (hallucinations) or believe things that aren't true (delusions). Hallucinations or delusions, together called psychosis, occur in up to 60% of PD patients at some point in time. Parkinson's disease psychosis can sometimes be associated with decreased quality of life, increased nursing home placement, increased rate of death, and greater caregiver burden. There are approximately 50,000 Veterans with Parkinson's disease receiving care in the VA, and up to 30,000 (60%) of them will experience psychosis at some point in time. Quetiapine is an antipsychotic drug approved by the Food and Drug Administration (FDA) that is the most commonly used medication to treat PD psychosis, but more studies are needed to determine if it works for this condition and is also well tolerated and safe. Pimavanserin is a newer antipsychotic drug approved by the Food and Drug Administration (FDA) specifically to treat PD psychosis, but more studies are needed to determine if it works and its safety. The purpose of this research is to gather additional information on the safety and effectiveness of both Quetiapine and Pimavanserin. By doing this study, the investigators hope to learn which of these medications is the most effective course of treatment for people with PD psychosis.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4
Age:40+

358 Participants Needed

Zoledronic Acid for Parkinson's Disease

Chicago, Illinois
This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 2650 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the National Institute of Aging.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Age:60+

2650 Participants Needed

NEU-411 for Parkinson's Disease

Chicago, Illinois
The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic profile. A DNA test will be used to identify the "LRRK2-driven" population with predicted elevation in the LRRK2 pathway. Participants will: • Take NEU-411 or placebo every day for 52 weeks

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:40 - 80

150 Participants Needed

Varenicline for Parkinson's Disease

Ann Arbor, Michigan
This trial aims to test whether one year of Varenicline, when compared to placebo, can reduce fall risk and show improvement in the ability to multitask while walking. Participants that are eligible after screening for the study will be randomized to receive Varenicline or placebo. Along with the study medication participants will have visits (over the phone and in person), various tests and imaging, questionnaires, and laboratory collections.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:45+

102 Participants Needed

Gene Therapy for Parkinson's Disease

Madison, Wisconsin
The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:45 - 75

87 Participants Needed

BIA 28-6156 for Parkinson's Disease

Farmington Hills, Michigan
This trial is testing a new drug called BIA 28-6156 to see if it can slow down movement problems in people with Parkinson's disease who have a specific genetic mutation. The study will compare the drug to another treatment over a period of several months.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:35 - 80

237 Participants Needed

IkT-148009 for Parkinson's Disease

Milwaukee, Wisconsin
This trial tests the safety and effects of IkT-148009, a daily pill, in people aged 30 to 80 with untreated Parkinson's disease. The drug aims to block an enzyme that may help manage symptoms. Participants will take the drug for a few months.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:30 - 80

120 Participants Needed

BIIB122 for Early-Stage Parkinson's Disease

Farmington Hills, Michigan
This trial is testing a new drug called BIIB122 to see if it can slow down symptoms in people with early-stage Parkinson's disease. The drug works by blocking a protein that may cause the disease to get worse. Participants will take the drug for several years to see if it helps.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:30 - 80

650 Participants Needed

Citalopram for Parkinson's Disease

Ann Arbor, Michigan
This trial will test if taking citalopram for a long period can reduce harmful brain plaques in older adults with Parkinson's disease. The goal is to see if this can help prevent or slow down memory and thinking problems. The study involves patients aged 65 and older who do not have depression. Citalopram has been observed to improve motor performance in Parkinson's disease patients when combined with levodopa.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:65+

58 Participants Needed

rTMS for Cognitive Impairment in Parkinson's Disease

Hines, Illinois
The purpose of this study is to examine safety, feasibility, and the behavioral and brain effects of a non-invasive treatment, repetitive transcranial magnetic stimulation (rTMS), for Veterans with Parkinson's disease or atypical parkinsonism and mild impairments in their thinking. The hypothesis is that rTMS can improve thinking for people with Parkinson's disease or atypical parkinsonism who are experiencing mild problems with their thinking ability.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:50+

56 Participants Needed

Resistant Maltodextrin for Parkinson's Disease

Chicago, Illinois
This trial will test if a special type of dietary fiber called resistant maltodextrin is safe and can help improve gut health and symptoms in people with Parkinson's disease. The fiber works by feeding good bacteria in the gut.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:60+

30 Participants Needed

VENT-02 for Parkinson's Disease

Farmington Hills, Michigan
This trial is a randomized, double-blind, placebo-controlled Phase 1b study evaluating the safety/tolerability, PK, and pharmacodynamics of VENT 02, administered orally at 1 dose level twice daily (BID) over 28 days in patients with mild to moderate Parkinson's disease. The study includes a screening period, a 28-day double-blind treatment period, and a 7-day follow-up period after last dose. Approximately 30 patients will be randomized into 1 of the 2 treatment arms.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:45 - 90

30 Participants Needed

Why Other Patients Applied

"I have 5 kids. I'll do anything I can to slow this disease down in hopes that I can stay active with them into their adulthood. I also feel I am serving the greater good for all those who suffer from Parkinson's. Since I'm self employed, my schedule is flexible. "

UR
Parkinson's PatientAge: 53

"I wasn’t diagnosed until February, but I showed symptoms over ten years before. I want to help find a cure. I have lost family members to Parkinson’s and want to contribute to the search for better treatments before my children possibly come down with it."

YX
Parkinson's PatientAge: 61

"It seems my Parkinson’s is progressing more rapidly now. And my meds are lagging behind. My off time is more frequent and the episodes are longer. Trying to figure out what my options are."

TM
Parkinson's PatientAge: 58

"My dad was in a research group for Parkinson's for about 6 years, which was very interesting. I was just diagnosed 1.5 years ago, and started on low dose Sinemet. Doing well on Sinemet, but I'd like to get ahead of the condition. I'm excited about participating in research. "

LN
Parkinson's PatientAge: 74

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

TB006 for Parkinson's Disease

Northbrook, Illinois
The primary objectives of this study are to assess the efficacy of TB006 in improving motor function and to assess the safety of TB006 in participants with Parkinson's Disease (PD).

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:50 - 80

62 Participants Needed

NE3107 for Parkinson's Disease

Farmington Hills, Michigan
The goal of this clinical trial is to learn if bezisterim can treat movement symptoms of Parkinson's disease in patients that are 45 to 80 years old, in generally good physical and mental health, and are nearing the need for treatment to relieve their symptoms but have not yet been prescribed any form of levodopa or drug with similar activity. The main questions it aims to answer are: * Will bezisterim decrease movement symptoms of Parkinson's disease? * What medical problems do participants have when taking bezisterim? Researchers will compare the effects of bezisterim treatment to placebo (a look-alike substance that contains no drug) to see if bezisterim works to treat movement symptoms of Parkinson's disease. Participants will * have a physical examination that includes an electrocardiogram * take drug or placebo twice daily for four months * visit a clinical site or receive an at home visit seven times over the course of five months

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:45 - 80

60 Participants Needed

Gene Therapy for Parkinson's Disease

West Bloomfield, Michigan
The objective of this study is to evaluate the long-term safety of AAV-GAD delivered bilaterally to the subthalamic nuclei (STN) in participants with Parkinson's disease.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Phase 1, 2
Age:25 - 86

14 Participants Needed

Lenrispodun for Parkinson's Disease

Milwaukee, Wisconsin
This trial is testing a medication called Lenrispodun to help people with Parkinson's Disease. It aims to reduce symptoms that appear when their usual medication stops working and to control involuntary movements caused by their current treatment. The study involves an initial check-up, a phase where patients receive either Lenrispodun or another substance, and a later check-up to ensure safety.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:40 - 80

132 Participants Needed

KM-819 for Parkinson's Disease

Royal Oak, Michigan
This trial is testing KM-819, a new drug, to see if it can stop or slow down Parkinson's disease. It involves healthy older adults and people with Parkinson's disease. Researchers aim to find out if KM-819 is safe and can improve symptoms and daily function in these patients.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:40+

314 Participants Needed

Prasinezumab for Early Parkinson's Disease

West Bloomfield, Michigan
This trial is testing an IV drug called prasinezumab in people with early-stage Parkinson's Disease who are already on stable medication. The drug aims to slow down the disease by attaching to a harmful protein in the brain. Researchers want to see if it works effectively.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:50 - 85

586 Participants Needed

CTC-413 for Parkinson's Disease

Farmington Hills, Michigan
This trial tests a combination of Pramipexole ER and Aprepitant in patients with idiopathic Parkinson's disease. Pramipexole ER helps reduce Parkinson's symptoms by mimicking dopamine, while Aprepitant prevents nausea to improve tolerance of the treatment. Pramipexole is used to treat Parkinson's disease and is effective in both early and advanced stages.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:40 - 80

24 Participants Needed

Prasinezumab for Early Parkinson's Disease

West Bloomfield, Michigan
This multicenter, randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy of intravenous prasinezumab (RO7046015/PRX002) versus placebo over 52 weeks in participants with early Parkinson's Disease (PD) who are untreated or treated with monoamine oxidase B (MAO-B) inhibitors since baseline. The study will consist of three parts: a 52-week, double-blind, placebo-controlled treatment period (Part 1) after which eligible participants will continue into an all-participants-on-treatment blinded dose extension for an additional 52 weeks (Part 2). Participants who complete Part 2 (including the 12-week treatment-free follow up visit assessing long term safety and efficacy of RO7046015) will be offered participation in Part 3 open-label extension (all-participants-on-RO7046015-treatment) for an additional 520 weeks.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:40 - 80

316 Participants Needed

Continuous Subcutaneous Infusion of Levodopa/Carbidopa for Parkinson's Disease

West Bloomfield, Michigan
This trial tests a pump that delivers medication under the skin for patients with advanced Parkinson's Disease. The treatment aims to improve movement symptoms by increasing dopamine levels in the brain. This method has been used for many years to manage motor complications in advanced Parkinson's Disease.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:30+

214 Participants Needed

PR001 for Parkinson's Disease

Chicago, Illinois
This trial is testing a new treatment called LY3884961 for people with moderate to severe Parkinson's disease who have a specific genetic mutation. The treatment is given directly into the brain to see if it can help improve their symptoms. The study will last for several years to monitor safety and effectiveness.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:35 - 80

20 Participants Needed

12

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Parkinson's Disease clinical trials in Michigan pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Parkinson's Disease clinical trials in Michigan work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Parkinson's Disease trials in Michigan 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Michigan for Parkinson's Disease is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Michigan several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Parkinson's Disease medical study in Michigan?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Parkinson's Disease clinical trials in Michigan?

Most recently, we added Exercise Program for Parkinson's Disease, Accelerated Brain Stimulation for Parkinson's Disease and Non-Invasive Vagal Nerve Stimulation for Parkinson's Disease to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials

Anxiety Clinical Trials

Schizophrenia Clinical Trials

ADHD Clinical Trials

Bipolar Disorder Clinical Trials

Multiple Sclerosis Clinical Trials

Autism Clinical Trials

Treatment Resistant Depression Clinical Trials

Borderline Personality Disorder Clinical Trials

Social Anxiety Disorder Clinical Trials

Parkinson's Disease Clinical Trials

Alzheimer's Disease Clinical Trials

By Location

Clinical Trials in California

Clinical Trials in Florida

Clinical Trials in Texas

Clinical Trials in New York

Clinical Trials in Ohio

Clinical Trials in Illinois

Clinical Trials in Pennsylvania

Clinical Trials in Michigan

Clinical Trials in North Carolina

Clinical Trials in Massachusetts

Clinical Trials in Missouri

Clinical Trials in Minnesota

Other People Viewed

By Subject

Top Clinical Trials near Foley, AL

169 Clinical Trials near Gig Harbor, WA

Top Lung Adenocarcinoma Clinical Trials

Top Clinical Trials near Fergus Falls, MN

Top Cerebral Palsy Clinical Trials

198 Clinical Trials near Michigan

30 Schizophrenia Trials near Fort Lauderdale, FL

Top Clinical Trials near California

Top Clinical Trials near Basalt, CO

Top Sleep Disorders Clinical Trials

59 Hypertension Trials near Olathe, KS

Top Clinical Trials near Dover, NJ

By Trial

Nivolumab + CCR2/5-inhibitor/Anti-IL-8 for Lung Cancer

CBM588 + Nivolumab + Cabozantinib for Kidney Cancer

Soda Intake Biomarkers in Healthy Diets

ACL Reconstruction With/Without Internal Bracing for Anterior Cruciate Ligament Injury

ESP Block for Pain After Kidney Stone Surgery

Communication + Substance Use Interventions for HIV

Immunosuppression Adjustment for Improved COVID-19 Vaccine Response

DASH vs Low-Carb Diet for Polycystic Ovary Syndrome

Tovorafenib + Pimasertib for Cancer

Cemiplimab for Skin Cancer

Zanubrutinib + Rituximab for Chronic Lymphocytic Leukemia

Caloric Restriction for Polycystic Kidney Disease

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial